Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in ImmunologyOpen Access

CD226+ B cells in primary Sjögren’s syndrome: a key player in clinical manifestations and disease pathogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

PZPing ZhaoSSSaizhe SongFirst Affiliated Hospital of Soochow UniversitySZSong Zhang

Discussion

Loading...

Member takes

Implication

Observational analysis uncovered increased CD226+ B cells in primary Sjögren’s syndrome, suggesting diagnostic and therapeutic implications.

Key Points

  • CD226+ B cells show strong correlation with clinical features and disease activity in primary Sjögren’s syndrome.
  • Significantly elevated CD226 expression was detected in CD19+ B cells of patients, indicating pathogenic roles.
  • Multicolor flow cytometry revealed distinct B cell subsets associated with heightened activation and pro-inflammatory profiles.
  • The study highlights CD226 as a promising therapeutic target and biomarker for diagnosing primary Sjögren’s syndrome.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479c0b0https://doi.org/10.3389/fimmu.2025.1623774
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1CD69: from activation marker to metabolic gatekeeper2017 · 996 citations